Pre-meal High-performance Inulin Supplementation in Healthy Non-diabetic Subjects
NCT ID: NCT04994353
Last Updated: 2021-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2020-12-14
2021-01-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes
NCT03794232
Prebiotics, Gut Microbiota, and Cardiometabolic Health
NCT02346838
Mulberry Leaf Extract and Blood Glucose Control in Diabetics
NCT01305434
The Effects of Vegetable Preloading on Postprandial Glycemia, Insulinaemia and Gastric Emptying
NCT06640335
Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin
NCT01039662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Experimental design This experimental design adapted a single-arm trial analysis. A group of 8 subjects received intervention with single pre-meal supplementation. After that, the glycaemic response was measured (see blood sampling preparation). This intervention was repeated every week with five different supplementation formulae (see below) for five consecutive weeks. The difference in their glycaemic response after meal for every intervention was measured and analyzed statistically.
Supplement preparation: Inulin formulations, isomaltooligosaccharides formulations, the combination of inulin and isomaltooligosaccharides formulations, dextrose solution, and vehicle-glucose formulations.
For the first week, the investigators measured glycaemic response to a meal without any intervention and use those data as a baseline. For the intervention, the investigators used the untreated control without supplementation (NS), HP Inulin formulations (IF), isomaltooligosaccharides/IMO formulations (IM, this formulation is marketed as Fibercreme®), the combination of HP inulin and IMO formula (MF), dextrose solution (DS), and vehicle-glucose formulations (VO) in the form of powder. All the supplementation formulas are purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia). The detailed composition of each formulation could be seen in Supplementary Table 1. For the preparation of 20% IF, IM, and MF solution, 20 grams of designated powder was diluted in 100 ml distilled water. For 20% DS, 20 grams of purified dextrose monohydrate was diluted in 100 ml distilled water. IMO solution was chosen as a control because IMO could act as partially digestible dietary fibre.43 Vehicle-glucose could act as a negative control for IF intervention because IF contains similar ingredients with the IF, but instead of inulin, glucose syrup was added as the caloric source.
Intervention: fasting, pre-meal supplementation, and meal Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. Supplement formula solution 20% (w/v) then given orally before a meal for five consecutive weeks in the following orders: IF in the first week, followed by IM in the second week, MF in the third week, DS in the fourth week, and VO in the last week. The meal for experimental subjects was given after intervention and contained 470 kcal "Ready Meal". The amount of calories in "Ready-Meal" is 25-30% from the calculated EER (see table 1). The macronutrient composition of the "Ready Meal" was purchased from PT. Charoen Pokphand Indonesia,TbK (Jakarta, Indonesia) was listed in supplementary table 2.
Blood sampling preparation, blood glucose, and glycaemic response (iAUC) measurement.
An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA). Blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. The first measurement at 0 representing the fasting plasma glucose (FPG), that is the blood glucose concentration after an overnight fast (10-12 hours). The glycaemic response measurement unit at 0, 30, 60, 90, and 120 minutes for each subject was described as the incremental area under the curve (iAUC). The iAUC refers to actual body exposure to certain substances after their administration. The AUC depends on the rate of substance elimination from the body and its dose of administration. iAUC calculation (symbolized with A) was carried out using a linear trapezoidal method and formula (see supplementary figure 1) as described in the literature.44
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supplementation
Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are "food grade", purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia).
No supplementation
1st Week: No supplementation
High Performance (HP) Inulin
2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
Isomalto-oligosaccharide (IMO)
3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
Combination HP-Inulin and IMO
4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).
Ingredients: 20 gram IMO-HP Inulin "Mix" diluted with 100 ml distilled water.
Dextrose solution
5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
Glucose solution
6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No supplementation
1st Week: No supplementation
High Performance (HP) Inulin
2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
Isomalto-oligosaccharide (IMO)
3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
Combination HP-Inulin and IMO
4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).
Ingredients: 20 gram IMO-HP Inulin "Mix" diluted with 100 ml distilled water.
Dextrose solution
5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
Glucose solution
6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normal diet
* not under any medication
* not having any history of metabolic diseases
* not having abnormalities such as systemic hypertension (resting blood pressure more than 140/90 mmHg), impaired glucose tolerance (fasting blood glucose concentration between 100-126 mg/dL and oral glucose tolerance test or OGTT more than 140 mg/dL), and non-alcoholic fatty liver diseases (NAFLD).
Exclusion Criteria
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitas Katolik Widya Mandala Surabaya
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hendy Wijaya
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hendy Wijaya, MD.M.Biomed.
Role: PRINCIPAL_INVESTIGATOR
Faculty of Pharmacy, Universitas Katolik Widya Mandala Surabaya
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitas Katolik Widya Mandala Surabaya
Surabaya, East Java, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fevre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1151-1210. doi: 10.1016/S0140-6736(17)32152-9.
Lambadiari V, Korakas E, Tsimihodimos V. The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients. 2020 Jul 24;12(8):2204. doi: 10.3390/nu12082204.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
131/WM12/KEPK/DOSEN/T/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.